ESPE Abstracts

Background and Aims: Insulin pump therapy may o"er superior glycemic control compared to multiple daily injections (MDI) in specific populations. Closed-loop insulin delivery systems show promise but have limited data in the Saudi pediatric and young adult populations. This study aimed to evaluate the e#cacy of insulin pump therapy in children with type 1 diabetes previously treated with multiple daily injections.

Methods: This is a prospective study on patients with type 1 diabetes who were on MDI of insulin and were shifted to Tandem t:slim X2 with Control-IQ Automated Insulin at King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia. The study was approved by KFSHRC (Reference Number: 2231203).

Results: Seventy patients with type 1 diabetes were included with a mean age of 10 ± 3.21 years (range 2-15 years), comprising 31 males (44.3%) and 39 females (55.7%). Recurrent severe hypoglycemia at baseline was reported in 58 individuals (82.86%). Using Control-IQ, insulin dose decreased significantly from 0.9 U/kg/day at baseline to 0.7 U/kg/day, P = 0.232. The median HbA1C significantly reduced from 8.04% ± 3.2 at baseline to 7% ± 0.65, P = 0.000. Control-IQ use significantly improved percent time in range (70–180 mg/dL) compared to baseline (64.9 ± 10.8 vs. 45.1 ± 13.7.1, P = 0.000). Overall, 98.2% of participants met our prespecified goals of less than 2% time below 54 mg/dL. The median duration on the insulin pump was 5 months, with no reported adverse events.

Conclusion: In this cohort, Tandem t:slim X2 with Control-IQ Automated Insulin system significantly improved glycemic control when compared to multiple daily insulin injections.